A study testing whether a new weekly shot, tirzepatide, can help people lose weight.

Who can join: Adults 30 to 65, have obesity or are overweight, BMI 27+.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 10 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor University of VirginiaDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 24

What this study is for

Primary condition: Obesity & Overweight.

Full scientific study title: The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED).

Who can join

Age30 to 65SexAnyBMI27 to 40

Adults 30 to 65, have obesity or are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Men and women 30-65 years of age, postmenopausal women included
27-29.9 with an additional CVD risk factor or 30-40 kg/m2
For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension)
Willingness and adequate health to go on weight loss medication
The capability and willingness to provide written informed consent

Key exclusion criteria

Including but not limited to serious arrhythmias
Cardiomyopathy
Congestive heart failure
Stroke or transient ischemic attacks
Peripheral vascular disease

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Virginia1 site

University of Virginia
Charlottesville, Virginia
Damon L Swift, Ph.D.(434) 924-1436

Follow this trial

We email you if NCT07298915 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Scheduled start: August 2026. Expected completion: June 2027. Last updated on ClinicalTrials.gov: May 6, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.